VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration
Top Cited Papers
Open Access
- 22 May 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 4992
Abstract
Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis throughout the human body, influencing countless physiological and pathological processes, including tumor growth, preeclampsia, and retinal diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). In DR, VEGF promotes retinal neovascularization and intraretinal fluid accumulation, leading to complications like diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Regular intravitreal anti-VEGF injections are commonly used to manage PDR and DME, though repeated treatments are often required, and efficacy can be limited. AMD, a major cause of vision loss in older adults, is characterized by either dry or wet forms. While the dry form has not been shown to be influenced by VEGF, the choroidal neovascularization of wet AMD has strong associations with VEGF. Current treatment for wet AMD consists primarily of anti-VEGF injections, the gold standard of care, but is limited by varying patient responses, as treatments are often repeated every 4-8 weeks indefinitely. This review explores the pathogenic role of VEGF in both DR and AMD, discussing the molecular mechanisms underlying these diseases and the therapeutic approaches targeting VEGF. Despite advancements, the variability in treatment responses highlights the need for continued research to develop more effective therapies to prevent vision loss and blindness associated with these retinal diseases.Keywords
Funding Information
- NIH (EY033551, CA278054, DA056203)
This publication has 76 references indexed in Scilit:
- Biochemistry of the hypoxia-inducible factor hydroxylasesCurrent Opinion in Chemical Biology, 2024
- Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathyCochrane Database of Systematic Reviews, 2023
- Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathyCochrane Database of Systematic Reviews, 2023
- Faricimab: First ApprovalDrugs, 2022
- Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic RetinopathyJAMA Ophthalmology, 2021
- Age-Related Macular DegenerationMedical Clinics of North America, 2021
- Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2019
- Anti-vascular endothelial growth factor for neovascular age-related macular degenerationCochrane Database of Systematic Reviews, 2019
- Prolyl Hydroxylase Domain Protein 2 (PHD2) Mediates Oxygen-Induced Retinopathy in Neonatal MiceThe American Journal of Pathology, 2011
- A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision LossArchives of Ophthalmology (1950), 2001